Target Healthcare REIT (LON:THRL) Reaches New 52-Week High – Here’s Why

Target Healthcare REIT (LON:THRLGet Free Report) hit a new 52-week high during trading on Friday . The company traded as high as GBX 110 and last traded at GBX 108.80, with a volume of 43722 shares. The stock had previously closed at GBX 108.40.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group restated a “hold” rating and issued a GBX 101 target price on shares of Target Healthcare REIT in a report on Wednesday, May 6th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, Target Healthcare REIT presently has an average rating of “Hold” and a consensus target price of GBX 101.

Read Our Latest Analysis on Target Healthcare REIT

Target Healthcare REIT Stock Down 0.4%

The business has a 50-day simple moving average of GBX 103.73 and a two-hundred day simple moving average of GBX 101.36. The stock has a market capitalization of £669.86 million, a P/E ratio of 8.59, a PEG ratio of 1.48 and a beta of 0.53.

Target Healthcare REIT (LON:THRLGet Free Report) last announced its quarterly earnings results on Wednesday, March 18th. The company reported GBX 3.38 earnings per share for the quarter. Target Healthcare REIT had a return on equity of 10.73% and a net margin of 104.45%. On average, sell-side analysts forecast that Target Healthcare REIT will post 6.2219101 earnings per share for the current year.

Target Healthcare REIT Company Profile

(Get Free Report)

Our investment objective is to provide shareholders with an attractive level of income together with the potential for capital and income growth, from a portfolio of UK care homes, diversified by tenant, geography, and resident payment profile. We only invest in modern, purpose-built homes.

Featured Stories

Receive News & Ratings for Target Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Target Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.